Literature DB >> 19218571

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.

Geetha Ramachandran, Karunaianantham Ramesh, Agibothu K Hemanth Kumar, Ishaan Jagan, Mahalingam Vasantha, Chandrasekaran Padmapriyadarsini, Gopalan Narendran, Sikhamani Rajasekaran, Soumya Swaminathan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19218571     DOI： 10.1093/jac/dkp033

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  25 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

2.  Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.

Authors:  M Viljoen; M O Karlsson; T M Meyers; H Gous; C Dandara; M Rheeders
Journal:  Eur J Clin Pharmacol       Date:  2011-11-06       Impact factor: 2.953

3.  Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Authors:  Kevin C Brown; Mina C Hosseinipour; Janelle M Hoskins; Ranjit K Thirumaran; Hsiao-Chuan Tien; Ralf Weigel; Jean Tauzie; Ida Shumba; Jatinder K Lamba; Erin G Schuetz; Howard L McLeod; Angela D M Kashuba; Amanda H Corbett
Journal:  Pharmacogenomics       Date:  2011-11-23       Impact factor: 2.533

4.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

Review 5.  Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.

Authors:  Awewura Kwara; Geetha Ramachandran; Soumya Swaminathan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

6.  Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.

Authors:  Sumonmal Uttayamakul; Sirirat Likanonsakul; Weerawat Manosuthi; Nuanjun Wichukchinda; Thareerat Kalambaheti; Emi E Nakayama; Tatsuo Shioda; Srisin Khusmith
Journal:  AIDS Res Ther       Date:  2010-03-26       Impact factor: 2.250

7.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

8.  Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.

Authors:  Saran Vardhanabhuti; Edward P Acosta; Heather J Ribaudo; Patrice Severe; Umesh Lalloo; Nagalingeshwaran Kumarasamy; Frank Taulo; Joseph Kabanda; Olola Oneko; Prudence Ive; Pradeep Sambarey; Ellen S Chan; Jane Hitti; Francis Hong; Deborah McMahon; David W Haas
Journal:  J Infect Dis       Date:  2013-05-17       Impact factor: 5.226

9.  Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Authors:  Janine E Micheli; Leslie W Chinn; Sarah B Shugarts; Ashish Patel; Jeffrey N Martin; David R Bangsberg; Deanna L Kroetz
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

10.  Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF).

Authors:  Florian Eyer; Darren M Roberts; Nicholas A Buckley; Michael Eddleston; Horst Thiermann; Franz Worek; Peter Eyer
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.